TY - JOUR A1 - Wobser, Marion A1 - Schummer, Patrick A1 - Appenzeller, Silke A1 - Kneitz, Hermann A1 - Roth, Sabine A1 - Goebeler, Matthias A1 - Geissinger, Eva A1 - Rosenwald, Andreas A1 - Maurus, Katja T1 - Panel sequencing of primary cutaneous B-cell lymphoma JF - Cancers N2 - Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin’s lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhibiting a low propensity for systemic dissemination or fatal outcome. Up to now, only few studies have investigated underlying molecular alterations of PCFBCL with respect to somatic mutations. Objectives: Our aim was to gain deeper insight into the pathogenesis of PCFBCL and to delineate discriminatory molecular features of this lymphoma subtype. Methods: We performed hybridization-based panel sequencing of 40 lymphoma-associated genes of 10 cases of well-characterized PCFBCL. In addition, we included two further ambiguous cases of atypical B-cell-rich lymphoid infiltrate/B-cell lymphoma of the skin for which definite subtype attribution had not been possible by routine investigations. Results: In 10 out of 12 analyzed cases, we identified genetic alterations within 15 of the selected 40 target genes. The most frequently detected alterations in PCFBCL affected the TNFRSF14, CREBBP, STAT6 and TP53 genes. Our analysis unrevealed novel mutations of the BCL2 gene in PCFBCL. All patients exhibited an indolent clinical course. Both the included arbitrary cases of atypical B-cell-rich cutaneous infiltrates showed somatic mutations within the FAS gene. As these mutations have previously been designated as subtype-specific recurrent alterations in primary cutaneous marginal zone lymphoma (PCMZL), we finally favored the diagnosis of PCMZL in these two cases based on these molecular findings. Conclusions: To conclude, our molecular data support that PCFBCL shows distinct somatic mutations which may aid to differentiate PCFBCL from pseudo-lymphoma as well as from other indolent and aggressive cutaneous B-cell lymphomas. While the detected genetic alterations of PCFBCL did not turn out to harbor any prognostic value in our cohort, our molecular data may add adjunctive discriminatory features for diagnostic purposes on a molecular level. KW - B-cell lymphoma KW - primary cutaneous follicular B-cell lymphoma KW - targeted sequencing Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290330 SN - 2072-6694 VL - 14 IS - 21 ER - TY - JOUR A1 - Siegmund, Daniela A1 - Wagner, Jennifer A1 - Wajant, Harald T1 - TNF receptor associated factor 2 (TRAF2) signaling in cancer JF - Cancers N2 - Tumor necrosis factor (TNF) receptor associated factor-2 (TRAF2) has been originally identified as a protein interacting with TNF receptor 2 (TNFR2) but also binds to several other receptors of the TNF receptor superfamily (TNFRSF). TRAF2, often in concert with other members of the TRAF protein family, is involved in the activation of the classical NFκB pathway and the stimulation of various mitogen-activated protein (MAP) kinase cascades by TNFRSF receptors (TNFRs), but is also required to inhibit the alternative NFκB pathway. TRAF2 has also been implicated in endoplasmic reticulum (ER) stress signaling, the regulation of autophagy, and the control of cell death programs. TRAF2 fulfills its functions by acting as a scaffold, bringing together the E3 ligase cellular inhibitor of apoptosis-1 (cIAP1) and cIAP2 with their substrates and various regulatory proteins, e.g., deubiquitinases. Furthermore, TRAF2 can act as an E3 ligase by help of its N-terminal really interesting new gene (RING) domain. The finding that TRAF2 (but also several other members of the TRAF family) interacts with the latent membrane protein 1 (LMP1) oncogene of the Epstein–Barr virus (EBV) indicated early on that TRAF2 could play a role in the oncogenesis of B-cell malignancies and EBV-associated non-keratinizing nasopharyngeal carcinoma (NPC). TRAF2 can also act as an oncogene in solid tumors, e.g., in colon cancer by promoting Wnt/β-catenin signaling. Moreover, tumor cell-expressed TRAF2 has been identified as a major factor-limiting cancer cell killing by cytotoxic T-cells after immune checkpoint blockade. However, TRAF2 can also be context-dependent as a tumor suppressor, presumably by virtue of its inhibitory effect on the alternative NFκB pathway. For example, inactivating mutations of TRAF2 have been associated with tumor development, e.g., in multiple myeloma and mantle cell lymphoma. In this review, we summarize the various TRAF2-related signaling pathways and their relevance for the oncogenic and tumor suppressive activities of TRAF2. Particularly, we discuss currently emerging concepts to target TRAF2 for therapeutic purposes. KW - apoptosis KW - autophagy KW - B-cell lymphoma KW - cellular inhibitor of apoptosis 1/2 (cIAP1/2) KW - necroptosis KW - nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) KW - tumor necrosis factor (TNF) KW - TNF receptor associated factor 2 (TRAF2) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-286073 SN - 2072-6694 VL - 14 IS - 16 ER - TY - JOUR A1 - Wobser, Marion A1 - Siedel, Claudia A1 - Kneitz, Hermann A1 - Bröcker, Eva-Bettina A1 - Goebeler, Mathias A1 - Houben, Roland A1 - Geissinger, Eva T1 - Microvessel Density and Expression of Vascular Endothelial Growth Factor and its Receptors in Different Subtypes of Primary Cutaneous B-cell Lymphoma JF - Acta Dermato-Venereologica N2 - A proangiogenic micromilieu is associated with a worse prognosis in systemic lymphoma. Hence, targeting the tumour microenvironment and its vasculature has evolved as a promising novel treatment strategy. The role of tumour neoangiogenesis in cutaneous B-cell lymphoma, however, has not yet been elucidated. Therefore, we examined the expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 and VEGFR-2, as well as microvessel density by immunohistochemistry in paraffin-embedded specimens of different subtypes of primary cutaneous B-cell lymphomas, systemic diffuse large B-cell lymphoma, and cutaneous B-cell pseudolymphoma. Primary cutaneous large B-cell lymphoma (PCLBCL) were characterized by significantly higher intratumoral expression levels of VEGF and its receptors in comparison with the indolent lymphoma subtypes. Moreover, PCLBCL exhibited significantly higher intratumoral microvessel counts. Our study provides evidence that the most aggressive subtype of cutaneous B-cell lymphoma, PCLBCL, is characterized by a proangiogenic micromilieu. KW - microvessel density KW - vascular endothelial growth KW - B-cell lymphoma KW - subtypes Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128608 VL - 93 IS - 6 ER - TY - JOUR A1 - Herrmann, Ken A1 - Queiroz, Marcelo A1 - Huellner, Martin W. A1 - Barbosa, Felipe de Galiza A1 - Buck, Andreas A1 - Schaefer, Niklaus A1 - Stolzman, Paul A1 - Veit-Haibach, Patrick T1 - Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT JF - BMC Cancer N2 - Background: Use of FDG-PET/CT for staging and restaging of lymphoma patients is widely incorporated into current practice guidelines. Our aim was to prospectively evaluate the diagnostic performance of FDG-PET/MRI and WB-DW-MRI compared with FDG-FDG-PET/CT using a tri-modality PET/CT-MRI system. Methods: From 04/12 to 01/14, a total of 82 FDG-PET/CT examinations including an additional scientific MRI on a tri-modality setup were performed in 61 patients. FDG-PET/CT, FDG-PET/MRI, and WB-DW-MRI were independently analyzed. A lesion with a mean ADC below a threshold of 1.2 x 10\(^{-3}\) mm\(^2\)/s was defined as positive for restricted diffusion. FDG-PET/CT and FDG-PET/MRI were evaluated for the detection of lesions corresponding to lymphoma manifestations according to the German Hodgkin Study Group. Imaging findings were validated by biopsy (n = 21), by follow-up imaging comprising CT, FDG-PET/CT, and/or FDG-PET/MRI (n = 32), or clinically (n = 25) (mean follow-up: 9.1 months). Results: FDG-PET/MRI and FDG-PET/CT accurately detected 188 lesions in 27 patients. Another 54 examinations in 35 patients were negative. WB-DW-MRI detected 524 lesions, of which 125 (66.5 % of the aforementioned 188 lesions) were true positive. Among the 188 lesions positive for lymphoma, FDG-PET/MRI detected all 170 instances of nodal disease and also all 18 extranodal lymphoma manifestations; by comparison, WB-DW-MRI characterized 115 (67.6 %) and 10 (55.6 %) lesions as positive for nodal and extranodal disease, respectively. FDG-PET/MRI was superior to WB-DW-MRI in detecting lymphoma manifestations in patients included for staging (113 vs. 73), for restaging (75 vs. 52), for evaluation of high-(127 vs. 81) and low-grade lymphomas (61 vs. 46), and for definition of Ann Arbor stage (WB-DW-MRI resulted in upstaging in 60 cases, including 45 patients free of disease, and downstaging in 4). Conclusion: Our results indicate that FDG-PET/CT and FDG-PET/MRI probably have a similar performance in the clinical work-up of lymphomas. The performance of WB-DW-MRI was generally inferior to that of both FDG-PET-based methods but the technique might be used in specific scenarios, e.g., in low-grade lymphomas and during surveillance. KW - response evaluation KW - FDG-PET/MRI KW - FDG-PET/CT KW - FDG KW - WB-DW-MRI KW - whole-body KW - involvement KW - coefficient KW - lymphoma KW - B-cell lymphoma KW - diffusion weighted MRI KW - whole body MRI KW - Hodgkin-lymphoma KW - 1st International Workshop KW - malignant lymphoma KW - initial experience Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136039 VL - 15 IS - 1002 ER - TY - THES A1 - Jehn, Philipp T1 - Genetische Charakterisierung von Mantelzell-Lymphomen mittels komparativer genomischer Hybridisierung T1 - Genetic characterization of mantle cell lymphomas with comparative genomic hybridization N2 - Mantelzell-Lymphome gehören mit einem Anteil von ca. 5-10 % der B-Zellneoplasien zu den aggressiven lymphatischen Tumoren und sind, neben der histologisch-morphologischen und klinischen Präsentation, in der überwiegenden Mehrzahl der Fälle durch eine chromosomale Translokation t(11;14) sowie die Expression der Oberflächenmarker CD5, CD20 und Cyclin D1 gekennzeichnet (sog. Cyclin D1-posive Tumoren). Bei einigen fehlt jedoch eine Expression von Cyclin D1 (sog. Cyclin D1-negative Tumoren). Gegenstand der vorliegenden Arbeit war die genetische Charakterisierung von 77 Mantellzell-Lymphomen mittels komparativer genomischer Hybridisierung, die Detektion vorhandener chromosomaler Imbalanzen sowie der Vergleich beider Gruppen bezüglich ihrer Aberrationsmuster. N2 - Mantle cell lymphomas (MCL) are about 5-10 % of B-cell neoplasia and are according to the aggressive forms of lymphatic tumors. They are characterized by a chromosomal translocation t(11;14) and expression of the surface antigens CD5, CD20 and cyclin D1 in the majority of cases (cyclin D1-positive MCL). But some of the tumors lack expression of cyclin D1 (cyclin D1-negative MCL). In this study 77 mantle cell lymphomas are characterized by comparative genomic hybridization. Furthermore the detected aberrations are compared between the cyclin D1- positive and the cyclin D1-negative cases. KW - Non-Hodgkin-Lymphom KW - B-Zell-Lymphom KW - Lymphom KW - Malignes Lymphom KW - Mantelzell-Lymphom KW - Mantelzellen KW - komparative genomische Hybridisierung KW - lymphatische Tumoren KW - Lymphome KW - mantle cell lymphoma KW - lymphoma KW - B-cell lymphoma KW - CGH KW - NHL Y1 - 2008 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-28958 ER - TY - THES A1 - Blenk, Steffen T1 - Bioinformatical analysis of B-cell lymphomas T1 - Bioinformatische Analyse von B-Zell Lymphomen N2 - Background: The frequency of the most observed cancer, Non Hodgkin Lymphoma (NHL), is further rising. Diffuse large B-cell lymphoma (DLBCL) is the most common of the NHLs. There are two subgroups of DLBCL with different gene expression patterns: ABC (“Activated B-like DLBCL”) and GCB (“Germinal Center B-like DLBCL”). Without therapy the patients often die within a few months, the ABC type exhibits the more aggressive behaviour. A further B-cell lymphoma is the Mantle cell lymphoma (MCL). It is rare and shows very poor prognosis. There is no cure yet. Methods: In this project these B-cell lymphomas were examined with methods from bioinformatics, to find new characteristics or undiscovered events on the molecular level. This would improve understanding and therapy of lymphomas. For this purpose we used survival, gene expression and comparative genomic hybridization (CGH) data. In some clinical studies, you get large data sets, from which one can reveal yet unknown trends. Results (MCL): The published proliferation signature correlates directly with survival. Exploratory analyses of gene expression and CGH data of MCL samples (n=71) revealed a valid grouping according to the median of the proliferation signature values. The second axis of correspondence analysis distinguishes between good and bad prognosis. Statistical testing (moderate t-test, Wilcoxon rank-sum test) showed differences in the cell cycle and delivered a network of kinases, which are responsible for the difference between good and bad prognosis. A set of seven genes (CENPE, CDC20, HPRT1, CDC2, BIRC5, ASPM, IGF2BP3) predicted, similarly well, survival patterns as proliferation signature with 20 genes. Furthermore, some bands could be associated with prognosis in the explorative analysis (chromosome 9: 9p24, 9p23, 9p22, 9p21, 9q33 and 9q34). Results (DLBCL): New normalization of gene expression data of DLBCL patients revealed better separation of risk groups by the 2002 published signature based predictor. We could achieve, similarly well, a separation with six genes. Exploratory analysis of gene expression data could confirm the subgroups ABC and GCB. We recognized a clear difference in early and late cell cycle stages of cell cycle genes, which can separate ABC and GCB. Classical lymphoma and best separating genes form a network, which can classify and explain the ABC and GCB groups. Together with gene sets which identify ABC and GCB we get a network, which can classify and explain the ABC and GCB groups (ASB13, BCL2, BCL6, BCL7A, CCND2, COL3A1, CTGF, FN1, FOXP1, IGHM, IRF4, LMO2, LRMP, MAPK10, MME, MYBL1, NEIL1 and SH3BP5; Altogether these findings are useful for diagnosis, prognosis and therapy (cytostatic drugs). N2 - Hintergrund: Die Häufigkeit von Non-Hodgkin-Lymphomen (NHL), den am meisten beobachteten Krebserkrankungen, steigt weiter an. Von den aggressiven Non-Hodgkin-Lymphomen (NHL) macht das “großzellige, diffuse B-Zell-Lymphom” (DLBCL) den größten Anteil aus. Durch Genexpressionsmuster wurden zwei Subtypen definiert: ACB (“Activated B-like DLBCL”) und GCB (“Germinal Center B-like DLBCL”). Die Patienten der Gruppe ABC sterben ohne Therapie oft innerhalb weniger Monate, weil der ABC Typ einen aggressiveren Krankheitsverlauf aufweist. Ein weiteres, von einer malignen Entartung der B-Lymphozyten ausgehendes Lymphom, ist das “Mantelzell Lymphom” (MCL). Es tritt selten auf und ist ebenfalls mit einer schlechten Prognose verbunden. Eine vollständige Heilung nach der Therapie ist sehr selten. Methoden: In diesem Projekt wurden diese B-zell Lymphome mit bioinformatischen Methoden untersucht, um auf molekularer Ebene neue Eigenschaften oder bisher unentdeckte Zusammenhänge zu finden. Das würde das Verständnis und damit auch die Therapie voranbringen. Dafür standen uns Überlebens-, Genexpressions- und chromosomale Aberrationsdaten zur Verfügung. Sie sind die bevorzugte Wahl der Mittel, um genetische Veränderungen in Tumorzellen zu bestimmen. Hierbei fallen oft große Datenmengen an, aus welchen man mit bioinformatischen Methoden vorher unerkannte Trends und Hinweise identifizieren kann. Ergebnisse (MCL): Explorative Analysen sowohl der Genexpressions- (zweite Hauptachse der Korrespondenz Analyse) als auch der chromosomalen Aberrationsdaten des Mantelzell-Lymphom zeigten uns hierbei, daß es trotz der linearen Korrelation zwischen der veröffentlichten Proliferationssignatur und der Überlebenszeit sinnvoll ist, in den Patienten (n=71) zwei Ausprägungen zu betrachten: Patienten mit schlechter und mit guter Prognose. Statistische Tests (moderate t-test, Wilcoxon rank-sum test) dieser beiden Typen zeigten Unterschiede im Zellzyklus und ein Netzwerk von Kinasen auf, welche für den Unterschied zwischen guter und schlechter Prognose verantwortlich sind. Sieben Gene (CENPE, CDC20, HPRT1, CDC2, BIRC5, ASPM, IGF2BP3) konnten gefunden werden, die eine ähnliche gute Prognose für Überlebenszeiten ermöglichen, wie eine früher veröffentlichte Proliferationssignatur mit 20 Genen. Außerdem konnten chromosomale Banden durch eine explorative Analyse mit der Prognose assoziiert werden (Chromosom 9: 9p24, 9p23, 9p22, 9p21, 9q33 and 9q34). Ergebnisse (DLBCL): Durch geeignete Normalisierung der Genexpressionsdaten von 248 DLBCL-Patienten trennte der Signatur basierte Predictor die Risikogruppen nun besser auf. Eine ähnlich gute Auftrennung konnte von uns sogar mit sechs Genen erreicht werden. Die explorative Analyse der Genexpressionsdaten konnte die Subtypen ABC und GCB als valide Gruppen bestätigen. In den Genen, die ABC und GCB unterscheiden, ergab sich eine Häufung in späten und frühen Zellzyklusstadien. Klassische Lymphommarker, neu aufgefundene spezielle Gene und Zellzyklusgene bilden ein Netzwerk, das die ABC und GCB Gruppen klassifizieren und Unterschiede in deren Regulation erklären kann (ASB13, BCL2, BCL6, BCL7A, CCND2, COL3A1, CTGF, FN1, FOXP1, IGHM, IRF4, LMO2, LRMP, MAPK10, MME, MYBL1, NEIL1 and SH3BP5. Dies ist auch für die Diagnose, Prognose und Therapie (Zytostatika) interessant. KW - Bioinformatik KW - Genexpression KW - Auswertung KW - B-Zell-Lymphom KW - Diffuses großzelliges B-Zell-Lymphom KW - Mantelzell-Lymphom KW - Bioinformatics KW - gene expression KW - B-cell lymphoma KW - Diffuse large B-cell lymphoma (DLBCL) KW - Mantle cell lymphoma (MCL) Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-27421 ER -